{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:40:11Z","timestamp":1794847211030,"version":"4.9.1"},"reference-count":45,"publisher":"FapUNIFESP (SciELO)","issue":"8","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"abstract":"<jats:p>Resumo: Em abril de 2019, foi assinada a portaria de incorpora\u00e7\u00e3o do medicamento nusinersena no Sistema \u00danico de Sa\u00fade (SUS). \u00c9 o medicamento mais caro j\u00e1 incorporado ao SUS, para uso no tratamento de atrofia muscular espinhal 5q tipo I. A incorpora\u00e7\u00e3o \u00e9 referida como um marco na tomada de decis\u00e3o sobre novas tecnologias no SUS, a ser viabilizada por meio de acordo de partilha de risco. O trabalho discute o processo de incorpora\u00e7\u00e3o do nusinersena, destacando aspectos contextuais, temporais e t\u00e9cnicos, al\u00e9m de poss\u00edveis consequ\u00eancias para a institucionaliza\u00e7\u00e3o da avalia\u00e7\u00e3o de tecnologias em sa\u00fade (ATS) no SUS. Seguiu m\u00e9todo explorat\u00f3rio, com revis\u00e3o de informa\u00e7\u00f5es p\u00fablicas produzidas pela Comiss\u00e3o de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC) e busca em bancos de dados governamentais de pre\u00e7os e compras. Foi produzida linha temporal descrevendo os pontos-chave do processo de incorpora\u00e7\u00e3o. Houve dois pedidos de incorpora\u00e7\u00e3o do medicamento. O primeiro, submetido pela Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos (SCTIE) do Minist\u00e9rio da Sa\u00fade, negado por unanimidade, em novembro de 2018. Seguiu-se o pedido do Secret\u00e1rio da SCTIE \u00e0 Advocacia-Geral da Uni\u00e3o (AGU), para que pudesse decidir de forma contr\u00e1ria \u00e0 recomenda\u00e7\u00e3o do plen\u00e1rio da CONITEC. A AGU recomendou uma nova submiss\u00e3o, feita pela empresa produtora e aprovada por unanimidade, em mar\u00e7o de 2019. N\u00e3o houve acr\u00e9scimo de novas evid\u00eancias ou redu\u00e7\u00e3o de pre\u00e7o que justificassem a mudan\u00e7a de decis\u00e3o. N\u00e3o foram identificados os elementos constituintes do acordo de partilha de risco. S\u00e3o sinalizados problemas de transpar\u00eancia e accountability, bem como riscos ao processo de institucionaliza\u00e7\u00e3o da ATS que vinha em curso no SUS.<\/jats:p>","DOI":"10.1590\/0102-311x00099619","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T19:39:54Z","timestamp":1566675594000},"source":"Crossref","is-referenced-by-count":12,"title":["A incorpora\u00e7\u00e3o do nusinersena no Sistema \u00danico de Sa\u00fade: uma reflex\u00e3o cr\u00edtica sobre a institucionaliza\u00e7\u00e3o da avalia\u00e7\u00e3o de tecnologias em sa\u00fade no Brasil"],"prefix":"10.1590","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-2453","authenticated-orcid":false,"given":"Ros\u00e2ngela","family":"Caetano","sequence":"first","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-2966","authenticated-orcid":false,"given":"Renata Curi","family":"Hauegen","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-7216","authenticated-orcid":false,"given":"Claudia Garcia Serpa","family":"Osorio-de-Castro","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref1","series-title":"Risk Sharing Agreements: acordos de partilha de risco e o sistema p\u00fablico de sa\u00fade no Brasil - oportunidades e desafios","author":"Haugen RC","year":"2014"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review","volume":"12","author":"Verhaart IEC","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/B978-0-444-64076-5.00038-7","article-title":"Spinal muscular atrophy","volume":"148","author":"Arnold ES","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras BT","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"ref5","series-title":"Consulta a medicamentos e hemoderivados"},{"key":"ref6","article-title":"Lei n\u00ba 12.401, de 28 de abril de 2011. Altera a Lei n\u00ba 8.080, de 19 de setembro de 1990, para dispor sobre a assist\u00eancia terap\u00eautica e a incorpora\u00e7\u00e3o de tecnologia em sa\u00fade no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2011","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref7","article-title":"Decreto n\u00ba 7.646, de 21 de dezembro de 2011. Disp\u00f5e sobre a Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade e sobre o processo administrativo para incorpora\u00e7\u00e3o, exclus\u00e3o e altera\u00e7\u00e3o de tecnologias em sa\u00fade pelo Sistema \u00danico de Sa\u00fade, e d\u00e1 outras provid\u00eancias","year":"2011","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref8","series-title":"Pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo para compras p\u00fablicas"},{"key":"ref9","series-title":"Pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo para compras p\u00fablicas"},{"key":"ref10","series-title":"Pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo para compras p\u00fablicas"},{"key":"ref11","series-title":"Pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo para compras p\u00fablicas"},{"key":"ref12","series-title":"Pre\u00e7os m\u00e1ximos de medicamentos por princ\u00edpio ativo para compras p\u00fablicas"},{"key":"ref13","series-title":"Nusinersena para o tratamento de pacientes com atrofia muscular espinhal 5q tipo I"},{"key":"ref14","series-title":"Ata da 69\u00aa Reuni\u00e3o da CONITEC"},{"key":"ref15","series-title":"Ata da 72\u00aa Reuni\u00e3o da CONITEC"},{"key":"ref16","series-title":"Tecnologias demandadas"},{"key":"ref17","series-title":"Parecer n\u00ba 01377\/2018\/CONJUR-MS\/CGU\/AGU"},{"key":"ref18","series-title":"Nusinersena para o tratamento de pacientes com atrofia muscular espinhal 5q"},{"key":"ref19","series-title":"Nusinersena para o tratamento de pacientes com atrofia muscular espinhal 5q"},{"key":"ref20","article-title":"Portaria n\u00ba 24, de 24 de abril de 2019. Torna p\u00fablica a decis\u00e3o de incorporar o nusinersena para atrofia muscular espinhal (AME) 5q tipo I, no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2019","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1590\/0102-311X00161812","article-title":"Evidence-based process for decision-making in the analysis of legal demands for medicines in Brazil","volume":"29","author":"Figueiredo TA","year":"2013","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"ref22","series-title":"Recurso Especial: REsp 1657156 RJ 2017\/0025629-7"},{"key":"ref23","article-title":"Stakeholder value judgments in decision-making on the incorporation, financing, and allocation of new health technologies in limited-resource settings a potential Brazilian approach","volume":"42","author":"Santoro Neto L","year":"2018","journal-title":"Rev Panam Salud P\u00fablica"},{"key":"ref24","series-title":"Nusinersena para atrofia muscular espinhal 5q. Contribui\u00e7\u00e3o para Consulta P\u00fablica n\u00ba 12 de 2019"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel RS","year":"2017","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2018.0869","article-title":"Concerns about the approval of nusinersen sodium by the US Food and Drug Administration","volume":"178","author":"Gerrity MS","year":"2018","journal-title":"JAMA Intern Med"},{"key":"ref27","first-page":"58","article-title":"Limiar de custo-efetividade uma necessidade para o Brasil?","volume":"8","author":"Pinto M","year":"2016","journal-title":"J Bras Econ Sa\u00fade"},{"key":"ref28","article-title":"Limiares de custo-efetividade e o Sistema \u00danico de Sa\u00fade","volume":"33","author":"De Soarez PC","year":"2017","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/qjmed\/hcu016","article-title":"Limits on use of health economic assessments for rare diseases","volume":"107","author":"Hyry HI","year":"2014","journal-title":"QJM"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy a systematic literature review","volume":"53","author":"Lin CW","year":"2015","journal-title":"Pediatr Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1017\/S0266462310000395","article-title":"Patients' perspectives in health technology assessment a route to robust evidence and fair deliberation","volume":"26","author":"Facey K","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S0266462310001315","article-title":"Introducing patients' and the public's perspectives to health technology assessment a systematic review of international experiences","volume":"27","author":"Gagnon MP","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"ref33","article-title":"Portaria n\u00ba 77, de 14 de dezembro de 2018. Torna p\u00fablica a decis\u00e3o de incorporar o eculizumabe para tratamento de pacientes com hemoglobin\u00faria parox\u00edstica noturna (HPN) no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2018","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref34","article-title":"Portaria n\u00ba 82, de 19 de dezembro de 2018. Torna p\u00fablica a decis\u00e3o de incorporar a alfaelosulfase para pacientes com mucopolissacaridose tipo IVa (MPS IVa; s\u00edndrome de Morquio A) no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2018","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref35","article-title":"Portaria n\u00ba 83, de 19 de dezembro de 2018. Torna p\u00fablica a decis\u00e3o de incorporar a galsulfase para a terapia de reposi\u00e7\u00e3o enzim\u00e1tica de longo prazo, em pacientes com diagn\u00f3stico confirmado de mucopolissacaridose tipo VI (defici\u00eancia de Nacetilgalactosamina 4-sulfa) no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","year":"2018","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with Evidence Development applications and issues","volume":"26","author":"Trueman P","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"ref37","series-title":"A review of Coverage with Evidence Development (CED) in different countries: what works and what doesn't.","author":"Br\u00fcgger U."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2190\/HS.41.2.h","article-title":"Coverage with evidence development for pharmaceuticals a policy in evolution?","volume":"41","author":"Lexchin J","year":"2011","journal-title":"Int J Health Serv"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1472-6963-10-153","article-title":"Risk sharing arrangements for pharmaceuticals potential considerations and recommendations for European payers","volume":"10","author":"Adamski J","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40258-014-0093-x","article-title":"Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers","volume":"12","author":"Carlson JJ","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"ref41","series-title":"Diretrizes metodol\u00f3gicas: avalia\u00e7\u00e3o de desempenho de tecnologias em sa\u00fade"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.22239\/2317-269x.01042","article-title":"Incorpora\u00e7\u00e3o de medicamentos sem registro sanit\u00e1rio no SUS um estudo das recomenda\u00e7\u00f5es da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no per\u00edodo 2012-2016","volume":"6","author":"Pedro EM","year":"2018","journal-title":"Vigil Sanit Debate"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12961-018-0319-8","article-title":"Challenges to decision-making processes in the national HTA agency in Brazil operational procedures, evidence use and recommendations","volume":"16","author":"Yuba TY","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1590\/0103-11042018s204","article-title":"Incorpora\u00e7\u00e3o de tecnologias no Sistema \u00danico de Sa\u00fade: as racionalidades do processo de decis\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade","volume":"42","author":"Souza KA","year":"2018","journal-title":"Sa\u00fade Debate"},{"key":"ref45","first-page":"29","article-title":"International survey of methods used in health technology assessment (HTA) does practice meet the principles proposed for good research?","volume":"2","author":"Stephens JM","year":"2012","journal-title":"Comp Eff Res"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csp\/v35n8\/1678-4464-csp-35-08-e00099619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:17:01Z","timestamp":1581121021000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2019001005010&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019]]}},"alternative-id":["S0102-311X2019001005010"],"URL":"https:\/\/doi.org\/10.1590\/0102-311x00099619","relation":{},"ISSN":["1678-4464","0102-311X"],"issn-type":[{"value":"1678-4464","type":"electronic"},{"value":"0102-311X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"article-number":"e00099619"}}